Invivoscribe To Present At Biotech Showcase™ 2019 In San Franciscowmm2019-07-04T21:02:41+00:00January 3rd, 2019|Categories: Press Releases|Tags: CDx, Companion Diagnostics, Dr. Jeffrey E. Miller Ph.D., EMA, FDA, PMDA, Streamlined CDx| ⟵ PRESS RELEASES PRESS RELEASE SAN FRANCISCO, [...] Read More
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.wmm2019-07-04T21:14:04+00:00August 1st, 2017|Categories: Press Releases|Tags: CDx, CE-Marked, CE-marked IVD Assay, FLT3, LeukoStrat, LeukoStrat® CDx FLT3 Mutation Assay| ⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...] Read More
Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AMLwmm2019-07-04T21:16:10+00:00April 28th, 2017|Categories: Press Releases|Tags: Acute Myeloid Leukemia, AML, CDx, Companion Diagnostics, FDA, FDA Approval, LeukoStrat, LeukoStrat® CDx FLT3 Mutation Assay, Rydapt®| ⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...] Read More